Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01093 CSPC PHARMA
RTNominal up4.990 +0.300 (+6.397%)
Research Report

24/11/2020 17:33

{I-bank focus}BOCOM cuts CSPC Pharma (01093) to HK$10.57

[ET Net News Agency, 24 November 2020] BOCOM International Research lowered its target
price for CSPC Pharmaceutical (01093) to HK$10.57 from HK$12.44 due to uncertainties over
price-cut on NBP and oncology drugs and maintained its "buy" rating.
The research house said CSPC's 9-month results are slightly above BOCOM's expectations.
It noted that key products sustained strong growth: Duomeisu +36.3%, Jinyouli +45.2%,
and Keaili +33.1%. The growth rates are expected to persist in FY2021, given the low base
this year. NBP was up 32.1%. Notably, Encun (clopidogrel bisulfate tablets) saw rapid
ramp-up after winning the bid in procurement with target quantity (PTQ).
BOCOM expects the growth for PTQ products to continue to accelerate next year.
Amphotericin B cholesterol sulfate complex/mitoxantrone liposomes are expected to obtain
approval in the near term/next year. (KL)

Remark: Real time quote last updated: 20/09/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.